Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/F2RL1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/F2RL1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/F2RL1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/F2RL1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00313413 | Stomach | CAG | regulation of cell killing | 11/552 | 99/18723 | 1.60e-04 | 3.63e-03 | 11 |
GO:00332093 | Stomach | CAG | tumor necrosis factor-mediated signaling pathway | 11/552 | 99/18723 | 1.60e-04 | 3.63e-03 | 11 |
GO:00026853 | Stomach | CAG | regulation of leukocyte migration | 17/552 | 210/18723 | 1.71e-04 | 3.79e-03 | 17 |
GO:003295631 | Stomach | CAG | regulation of actin cytoskeleton organization | 24/552 | 358/18723 | 1.71e-04 | 3.79e-03 | 24 |
GO:00706613 | Stomach | CAG | leukocyte proliferation | 22/552 | 318/18723 | 2.03e-04 | 4.32e-03 | 22 |
GO:19004263 | Stomach | CAG | positive regulation of defense response to bacterium | 4/552 | 11/18723 | 2.09e-04 | 4.32e-03 | 4 |
GO:011005331 | Stomach | CAG | regulation of actin filament organization | 20/552 | 278/18723 | 2.34e-04 | 4.68e-03 | 20 |
GO:00439033 | Stomach | CAG | regulation of biological process involved in symbiotic interaction | 9/552 | 72/18723 | 2.57e-04 | 5.05e-03 | 9 |
GO:00026883 | Stomach | CAG | regulation of leukocyte chemotaxis | 12/552 | 122/18723 | 2.61e-04 | 5.11e-03 | 12 |
GO:00509003 | Stomach | CAG | leukocyte migration | 24/552 | 369/18723 | 2.68e-04 | 5.22e-03 | 24 |
GO:20003793 | Stomach | CAG | positive regulation of reactive oxygen species metabolic process | 9/552 | 76/18723 | 3.88e-04 | 6.98e-03 | 9 |
GO:003009931 | Stomach | CAG | myeloid cell differentiation | 24/552 | 381/18723 | 4.26e-04 | 7.52e-03 | 24 |
GO:00341353 | Stomach | CAG | regulation of toll-like receptor 2 signaling pathway | 4/552 | 13/18723 | 4.32e-04 | 7.54e-03 | 4 |
GO:00026873 | Stomach | CAG | positive regulation of leukocyte migration | 12/552 | 135/18723 | 6.59e-04 | 1.06e-02 | 12 |
GO:00018193 | Stomach | CAG | positive regulation of cytokine production | 27/552 | 467/18723 | 7.24e-04 | 1.13e-02 | 27 |
GO:0007596 | Stomach | CAG | blood coagulation | 16/552 | 217/18723 | 7.37e-04 | 1.13e-02 | 16 |
GO:003297031 | Stomach | CAG | regulation of actin filament-based process | 24/552 | 397/18723 | 7.62e-04 | 1.17e-02 | 24 |
GO:0032677 | Stomach | CAG | regulation of interleukin-8 production | 10/552 | 102/18723 | 8.58e-04 | 1.28e-02 | 10 |
GO:0032637 | Stomach | CAG | interleukin-8 production | 10/552 | 103/18723 | 9.26e-04 | 1.37e-02 | 10 |
GO:0007599 | Stomach | CAG | hemostasis | 16/552 | 222/18723 | 9.40e-04 | 1.38e-02 | 16 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
F2RL1 | SNV | Missense_Mutation | rs185549069 | c.308N>A | p.Arg103Gln | p.R103Q | P55085 | protein_coding | deleterious(0.04) | benign(0.103) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
F2RL1 | SNV | Missense_Mutation | novel | c.946A>T | p.Ser316Cys | p.S316C | P55085 | protein_coding | tolerated(0.05) | possibly_damaging(0.882) | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | | SD |
F2RL1 | insertion | Nonsense_Mutation | novel | c.703_704insCACATAAGTTAGCATAACATGCTAA | p.Leu235SerfsTer6 | p.L235Sfs*6 | P55085 | protein_coding | | | TCGA-AN-A0FF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
F2RL1 | insertion | Frame_Shift_Ins | novel | c.947_948insAAATATTGATCTCTACATCCCCCAACACTCCA | p.Ser316ArgfsTer24 | p.S316Rfs*24 | P55085 | protein_coding | | | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | | SD |
F2RL1 | SNV | Missense_Mutation | novel | c.1076T>C | p.Leu359Pro | p.L359P | P55085 | protein_coding | deleterious(0) | probably_damaging(0.956) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
F2RL1 | SNV | Missense_Mutation | novel | c.998N>G | p.Ser333Cys | p.S333C | P55085 | protein_coding | deleterious(0.03) | probably_damaging(0.967) | TCGA-C5-A8YQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
F2RL1 | SNV | Missense_Mutation | novel | c.945N>C | p.Lys315Asn | p.K315N | P55085 | protein_coding | tolerated(0.26) | probably_damaging(0.913) | TCGA-EA-A97N-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
F2RL1 | SNV | Missense_Mutation | novel | c.1018N>A | p.Asp340Asn | p.D340N | P55085 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
F2RL1 | SNV | Missense_Mutation | novel | c.1019N>G | p.Asp340Gly | p.D340G | P55085 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AJ-A23O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
F2RL1 | SNV | Missense_Mutation | | c.376N>G | p.Ile126Val | p.I126V | P55085 | protein_coding | tolerated(0.34) | benign(0.012) | TCGA-AP-A054-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | | ERYTHROMYCIN | ERYTHROMYCIN | 18212111 |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | | AC-55541 | CHEMBL493076 | 18720984 |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | agonist | 178100874 | | |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | | ROXITHROMYCIN | ROXITHROMYCIN | 18212111 |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | antagonist | 381744949 | | |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | agonist | 178103272 | | |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | antagonist | 178103271 | | |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | agonist | 178100746 | | |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | agonist | 178103269 | | |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | antagonist | 178103270 | | |